NCT07625137Not yet recruiting
Preventing Ovarian Cancer Through Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy
Expanding Opportunistic Bilateral Salpingectomy to Laparoscopic Cholecystectomy to Prevent Ovarian Cancer: A Feasibility and Safety Trial
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
This study aims to evaluate the feasibility, safety, and cost-effectiveness of opportunistic salpingectomy (OS-the removal of the fallopian tubes) at the time of laparoscopic cholecystectomy (the removal of the gallbladder) to prevent ovarian cancer. Ovarian cancer is the fifth leading cause of cancer-related mortality in females in Canada. OS can prevent the most common and lethal type of ovarian cancer, high-grade serous carcinoma (HGSC). OS during gynecologic surgery (hysterectomy or instead of tubal ligation) is safe and effective. However, rates of hysterectomies and tubal sterilization are decreasing. This research team aims to extend the prevention of ovarian cancer by expanding to offer OS during other surgeries in the abdomen, when patients are already undergoing a surgical procedure. This study will examine: 1) the feasibility of OS at the time of laparoscopic cholecystectomy; 2) the safety of OS at the time of laparoscopic cholecystectomy; 3) any health services consequences of offering OBS during laparoscopic cholecystectomy. The hypothesis is that OS at the time of laparoscopic cholecystectomy is a feasible, safe, and cost-effective primary prevention strategy for ovarian cancer. It is also hypothesized that there will be 10-20 minutes of additional operating room time for completing OS, and that integrating the identified partners and knowledge users, as well as adding relevant knowledge users as the project progresses, will affect the rapid mobilization of our findings.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- First submitted
- 15 May 2026
- Start date
- 1 Jul 2026
- Primary completion date
- 31 Jan 2029
- Lead sponsor
- University of British Columbia
- Diseases
- Ovarian cancer
- NCT number
- NCT07625137
What you commit to
- Study type: Interventional
- Planned participants: 240
- From 1 Jul 2026 to the primary completion date, 31 Jan 2029
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Less than 24 hours available from surgeon consult to surgery
- Previously had a salpingectomy or salpingo-oophorectomy
Other
- Individuals with a desire for a future pregnancy
Who the study is looking for
- Individuals with fallopian tubes who are undergoing lap chole and have more than 24 hours from surgeon consult to surgery, regardless of menopausal status
- Age of 35 years and older
- Patient must be able to give oral and written informed consent
- Premenopausal patients will be included but will be counseled regarding their fertility
Age in the registry: 35 years to - · Sex: Female · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hamilton Health Sciences Center Coordinator of this site? Confirm its status | Hamilton | Canada | Unknown status |
| Langley Memorial Hospital Coordinator of this site? Confirm its status | Langley | Canada | Unknown status |
| Vancouver General Hospital (VGH) Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.